The clinical application of fluorescently-labeled monoclonal antibody against P-selectin

AIM: To investigate the clinical significance in determination of the P-selectin levels in subjects with prethrombotic state or thrombosis by flow cytometry (FCM). METHODS: The P-selectin expression on platelet membrane in 42 patients with diabetes mellitus, 33 with hyperlipidemia, 23 with cerebral infarction and 20 healthy individuals, were analyzed using fluorescently-labeled SZ-51 by direct FCM comparing with indirect FCM and enzyme-linked immunosorbent assay (ELISA). RESULTS: The level of P-selectin on platelet membrane is higher in DM (23.92%±15.83%), in hyperlipidemia (18.34%±9.46%) and in cerebral infarction (19.32%±10.38%) than normal subjects (3.38%±1.11%) (P<0.01). In addition, similar results on P-selectin were obtained by indirect FCM and ELISA in patients with DM and cerebral infarction. CONCLUSION: FITC-labeled SZ-51-IgG can be used in FCM, and it would be a new and sensitive method in detecting platelet activation.